The Antiatherogenic Effect of Fish Oil in Male Mice Is Associated with a Diminished Release of Endothelial ADAM17 and ADAM10 Substrates
- PMID: 25926412
- DOI: 10.3945/jn.115.211375
The Antiatherogenic Effect of Fish Oil in Male Mice Is Associated with a Diminished Release of Endothelial ADAM17 and ADAM10 Substrates
Abstract
Background: Growing evidence suggests that disintegrin and metalloprotease (ADAM) 17 (ADAM17) and ADAM10 contribute to the pathogenesis of vascular diseases. ADAM17 promotes inflammatory processes by liberating tumor necrosis factor α, interleukin 6 receptor (IL-6R), and tumor necrosis factor receptor 1 (TNFR1). ADAM17 and ADAM10 modulate vascular permeability by cleaving endothelial adhesion molecules such as junctional adhesion molecule A (JAM-A) and vascular endothelial cadherin (VE-cadherin), respectively.
Objective: This study was designed to investigate whether a link might exist between the protective effects of fish oil (FO) supplementation against atherosclerosis and ADAM function.
Methods: Male LDL receptor knockout (LDLR(-/-)) mice and male wild-type (WT) mice were fed a Western diet (200 g/kg fat, 1.5 g/kg cholesterol) containing either 20% lard (LDLR(-/-)-lard and WT-lard groups) or 10% lard combined with 10% FO (LDLR(-/-)-FO and WT-FO groups) for 12 wk. Atherosclerotic lesion development and fatty acid composition of liver microsomes were evaluated. ADAM10 and ADAM17 expression was determined by quantitative real-time polymerase chain reaction and immunoblot analyses. Concentrations of soluble ADAM substrates in plasma and liver extracts were measured by ELISA.
Results: Diets supplemented with FO markedly reduced development of early atherosclerotic lesions in LDLR(-/-) mice (LDLR(-/-)-lard group vs. LDLR(-/-)-FO group mean ± SD: 29.6 ± 6.1% vs. 22.5 ± 4.2%, P < 0.05). This was not accompanied by changes in expression of ADAM17 or ADAM10 in the aorta or liver. No dietary effects on circulating TNFR1 (LDLR(-/-)-lard group vs. LDLR(-/-)-FO group mean ± SD: 1.22 ± 0.23 vs. 1.39 ± 0.28, P > 0.2) or IL-6R (1.06 ± 0.12 vs. 0.98 ± 0.09 fold of WT-lard group, P > 0.1), classical substrates of ADAM17 on macrophages, and neutrophil granulocytes were observed. However, a reduction in atherosclerotic lesions in the LDLR(-/-)-FO group was accompanied by a significant reduction in the circulating endothelial cell adhesion molecules JAM-A (LDLR(-/-)-lard group vs. LDLR(-/-)-FO group mean ± SD: 1.42 ± 0.20 vs. 0.95 ± 0.56 fold of WT-lard group, P < 0.05), intercellular adhesion molecule 1 (1.15 ± 0.14 vs. 0.88 ± 0.17 fold of WT-lard group, P < 0.05), and VE-cadherin (0.88 ± 0.12 vs. 0.72 ± 0.15 fold of WT-lard group, P < 0.05), reflecting reduced ADAM activity in endothelial cells.
Conclusion: FO exerted an antiatherogenic effect on male LDLR(-/-) mice that was accompanied by a reduced release of ADAM17 and ADAM10 substrates from endothelial cells. It is suggested that FO-decreased ADAM activity contributes to improved endothelial barrier function and thus counteracts intimal lipoprotein insudation and macrophage accumulation.
Keywords: ADAM; LDLR knockout; atherosclerosis; endothelial permeability; fish oil; shedding.
© 2015 American Society for Nutrition.
Similar articles
-
Unsaturated fatty acids drive disintegrin and metalloproteinase (ADAM)-dependent cell adhesion, proliferation, and migration by modulating membrane fluidity.J Biol Chem. 2011 Jul 29;286(30):26931-42. doi: 10.1074/jbc.M111.243485. Epub 2011 Jun 3. J Biol Chem. 2011. PMID: 21642425 Free PMC article.
-
Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases.Blood. 2009 May 7;113(19):4799-809. doi: 10.1182/blood-2008-04-152330. Epub 2009 Mar 3. Blood. 2009. PMID: 19258599
-
ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin.Circ Res. 2008 May 23;102(10):1192-201. doi: 10.1161/CIRCRESAHA.107.169805. Epub 2008 Apr 17. Circ Res. 2008. PMID: 18420943 Free PMC article.
-
The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?Eur J Cell Biol. 2011 Jun-Jul;90(6-7):527-35. doi: 10.1016/j.ejcb.2010.11.005. Epub 2010 Dec 30. Eur J Cell Biol. 2011. PMID: 21194787 Review.
-
The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.Semin Cell Dev Biol. 2009 Apr;20(2):164-74. doi: 10.1016/j.semcdb.2008.09.005. Epub 2008 Sep 18. Semin Cell Dev Biol. 2009. PMID: 18951988 Review.
Cited by
-
Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression.Aging (Albany NY). 2019 Mar 29;11(6):1695-1715. doi: 10.18632/aging.101863. Aging (Albany NY). 2019. PMID: 30926762 Free PMC article.
-
Effect of Lentivirus-Mediated miR-499a-3p on Human Umbilical Vein Endothelial Cells.Biomed Res Int. 2020 Aug 26;2020:9372961. doi: 10.1155/2020/9372961. eCollection 2020. Biomed Res Int. 2020. PMID: 32908925 Free PMC article.
-
Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia-A Pilot Study.Nutrients. 2020 Apr 18;12(4):1137. doi: 10.3390/nu12041137. Nutrients. 2020. PMID: 32325781 Free PMC article.
-
Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease.Biomed Res Int. 2020 Nov 9;2020:2010728. doi: 10.1155/2020/2010728. eCollection 2020. Biomed Res Int. 2020. PMID: 33224974 Free PMC article. Review.
-
ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.Adv Pharmacol. 2022;94:255-363. doi: 10.1016/bs.apha.2021.11.002. Epub 2022 Jan 24. Adv Pharmacol. 2022. PMID: 35659374 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous